No Data
No Data
Zhao Bei's second-quarter report for ICBC Credit Suisse Fund has been released! Jiangsu Hengrui Pharmaceuticals (600276.SH) is the top holding.
On July 18th, the fund under Zhao Bei's management at ICBC Credit Suisse Fund released its Q2 report for 2024.
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
Market Chatter: Jiangsu Hengrui Medicine Vows to Improve Production Following FDA Warning
Jiangsu Hengrui Medicine (SHA:600276) said it will commit to enhancing its clean production processes after the US Food and Drug Administration found one of its plants in Jiangsu as non-compliant
Jiangsu Hengrui Pharmaceuticals (600276.SH): Currently, the company's export products to the USA are unaffected.
Jiangsu Hengrui Pharmaceuticals (600276.SH) stated on the interactive platform on July 17th that the FDA warning letter the company received this time is related to the previous Form 483, both of which are related to the inspection of a formulation production site in the Lianyungang area by the FDA. At present, the export of products to the United States is not affected, and there is no impact on the company's other production sites, which will not have a significant impact on the company's performance. In response to the improvement suggestions raised by the FDA in this warning letter, the company will actively organize internal and external experts and third-party consulting institutions to implement relevant suggestions, maintain close communication with the FDA, and strive to close the warning letter as soon as possible.
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Hengrui Medicine Gets Inspection Clearance From Jiangsu Province's Drug Regulator
Jiangsu Hengrui Medicine (SHA:600276) received a good manufacturing practice or GMP certificate from the drug regulator of China's Jiangsu Province after it passed regulatory inspection, according to
No Data